The Novacyt (NCYT) share price: is it set to soar again?

The Novacyt share price (LON: NCYT) collapsed earlier in 2021. But the latest news has sent it heading upwards again. Time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Novacyt (LSE: NCYT) was a bit of a stock market darling throughout 2020 and into 2021. A couple of super high peaks did quickly decline, but things were still looking pretty rosy.

But then in April, the NCYT share price suddenly nosedived. And since then it’s continued to drift downwards.

Until Wednesday, that is, when we saw the shares climb 20% in just one day. Before I get too excited about that though, I need to put it into perspective. This latest increase puts Novacyt up 24% over the past 12 months. But at its earlier peaks, in October 2020 and again in January 2021, we were looking at gains of 300%.

Should you invest £1,000 in Novacyt S.a. right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Novacyt S.a. made the list?

See the 6 stocks

Novacyt is a specialist in Covid-19 testing. We had been hoping for, and expecting, an effective vaccine since the very start of the pandemic. But it’s been clear for some time the virus will be with us for the long term, just like influenza. And testing demand will presumably continue with it.

The new Novacyt share price spike is down to a first-half update. Total revenue increased by 50% compared to the first half of 2020. Revenue from the firm’s contract with the UK’s Department of Health and Social Care (DHSC), which accounts for 43% of the total, jumped 121%.

Reasons for caution

That’s good, but I’m cautious over the comparatives with last year. They include a period when Novacyt was just getting started with its testing development, before sales had kicked off. My Motley Fool colleague Roland Head has raised a few concerns too, all of which I share. The most important issue, I think, is the reason for April’s price slump.

Novacyt had a contract with the DHSC for the provision of test kits, and expected it to be extended. It didn’t happen, and the announcement of the failure triggered the NCYT share price crash. In addition, there’s an ongoing legal dispute, and I fear that might prove expensive.

Further, it seems £40.8m of 2021 DHSC revenue is actually unpaid and still under dispute. That’s 43% of the first-half total. On the upside, the company still reckons it should achieve around £100m in non-DHSC revenue for the full year. But I really think I’d want to see how the dispute turns out before I’d consider buying.

NCYT share price valuation

On the upside, I can see demand for Covid testing continuing at high levels for the foreseeable future. And based solely on the mooted £100m revenue, Roland estimates a forward P/E multiple of only around seven. That, for a stock with growth potential, looks very attractive. And it does tempt me.

But I don’t know what the balance sheet looks like at the moment, and there are just too many uncertainties for me to invest right now. I generally tend to keep away from companies in legal disputes with their biggest customers too.

I’ll keep watching though, and hoping for future Novacyt share price dips.

Should you invest £1,000 in Novacyt S.a. right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Novacyt S.a. made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 12% in a week, should I jump on Nvidia stock today?

As the Nvidia stock price heads south, our writer is asking himself a trio of questions to decide whether to…

Read more »

Investing Articles

The Fresnillo share price gains after 2024 profits soar. Is it time to invest in silver demand?

A strong spell for precious metals has helped push up the Fresnillo share price in the past two years. And…

Read more »

Investing Articles

See what £20k invested in red-hot Lloyds shares on the first day of 2025 is worth now…

Harvey Jones is thrilled to see his Lloyds shares make a rip-roaring start to 2025. But have they gone too…

Read more »

Abstract 3d arrows with rocket
Investing Articles

See what £10k invested in this high-flying FTSE 250 defence stock 1 month ago is worth now!

This FTSE 250 defence technology stock’s rocketing on geopolitical uncertainty. After a blistering month, Harvey Jones asks can it continue…

Read more »

Inflation in newspapers
Investing Articles

As inflation hits Greggs shares, should investors consider snapping up a bargain?

Excerpt: A weak start to 2025 has sent Greggs shares down another 8%. Has the FTSE 250 stock reached a…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Could Nike help rescue the JD Sports share price?

Our writer considers whether Nike’s turnaround plan is working and whether it’ll help boost the JD Sports share price.

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Up 145%! This red-hot growth stock has flown completely under my radar!

Harvey Jones is casting envious glances at a FTSE 100 growth stock that rocketed the moment he turned his back…

Read more »

Investing Articles

How much does an investor need in a Stocks and Shares ISA to retire comfortably?

Investing regularly in a Stocks and Shares ISA can go a long way towards providing someone with enough cash to…

Read more »